IFNB1 and viral infectious disease: A recent double-blind RCT demonstrated that AIT significantly enhanced the bronchial epithelial antiviral resistance to viral infection by elevating the levels of interferon (IFN)-β and IFN-λ produced by bronchial epithelial cells after 24 weeks of treatment [11].